Quote | Nurix Therapeutics Inc. (NASDAQ:NRIX)
Last: | $18.93 |
---|---|
Change Percent: | 0.53% |
Open: | $20.8 |
Close: | $18.93 |
High: | $21.07 |
Low: | $18.865 |
Volume: | 841,886 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Nurix Therapeutics Inc. (NASDAQ:NRIX)
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
2024-06-19 09:27:56 ET Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional smal...
Message Board Posts | Nurix Therapeutics Inc. (NASDAQ:NRIX)
Subject | By | Source | When |
---|---|---|---|
https://ih.advfn.com/stock-market/NASDAQ/nurix-therapeutics-NRIX/stock-news/8889 | TheFinalCD | investorshub | 08/23/2022 11:04:42 PM |
what the F is wrong with this fkn | infamous | investorshub | 03/24/2021 7:21:29 PM |
$CEO: Dr. Arthur T. Sands | Phosphene | investorshub | 12/09/2020 11:20:59 PM |
Strategic partnerships with Sanofi and Gilead Sciences Inc. | Phosphene | investorshub | 12/08/2020 5:01:07 AM |
Data support a planned clinical trial of NX-2127 | Phosphene | investorshub | 12/08/2020 4:50:47 AM |
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal t...
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., P...